Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models

Toxicology in Vitro

Volumn 24, Issue 2, 2010, Pages 630-637

  Beghin, D ^a,b   Delongeas, J L ^b   Claude, N ^b   Farinotti, R ^a,c   Forestier, F ^a   Gil, S ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Culture; Drug safety; Human trophoblasts; P glycoprotein; Placenta; Rat trophoblasts; Therapeutic drugs

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOVASCULAR AGENT; GLYCOPROTEIN P; METHADONE; THALIDOMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD PLACENTA BARRIER; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTROPHOBLAST; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PLACENTA FUNCTION; PROTEIN EXPRESSION; RAT; RISK ASSESSMENT; SPECIES DIFFERENCE; TERATOGENICITY; TISSUE CULTURE; TROPHOBLAST;

ANIMALS; ASPIRIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; METHADONE; P-GLYCOPROTEIN; PLACENTA; PREGNANCY; RATS; RATS, WISTAR; THALIDOMIDE; TIME FACTORS; TROPHOBLASTS;

RATTUS;

EID: 76749147285     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.10.005     Document Type: Article

References (49)

1. Barker D.J. Intrauterine programming of adult disease. Mol. Med. Today 1 (1995) 418-423
2. Beghin D., Delongeas J.L., Claude N., Forestier F., Farinotti R., and Gil S. Development and characterisation of a new model of rat trophoblasts. Toxicol. In Vitro 23 (2009) 141-147
3. Botting J. The History of Thalidomide. Drug News Perspect. 15 (2002) 604-611
4. Bouer R., Barthe L., Philibert C., Tournaire C., Woodley J., and Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol. 13 (1999) 494-500
5. Carney E.W., Scialli A.R., Watson R.E., and DeSesso J.M. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Birth Defects Res. C. Embryo Today 72 (2004) 345-360
6. Carter A.M., Tanswell B., Thompson K., and Han V.K. Immunohistochemical identification of epithelial and mesenchymal cell types in the chorioallantoic and yolk sac placentae of the guinea-pig. Placenta 19 (1998) 489-500
7. Carter A.M. Evolution of the placenta and fetal membranes seen in the light of molecular phylogenetics. Placenta 22 (2001) 800-807
8. Chen W., Zhu J., Mirshahi F., Soria J., Mirshahi M., and Soria C. Thalidomide inhibits the angiogenic activity of culture supernatants of multiple myeloma cell line. Zhonghua Xue Ye Xue Za Zhi 23 (2002) 520-523
9. Cross J.C. Genetic insights into trophoblast differentiation and placental morphogenesis. Semin. Cell Dev. Biol. 11 (2000) 105-113
10. Essodaigui M., Broxterman H.J., and Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37 (1998) 2243-2250
11. Food and Drug Administration (FDA): Drug Interaction Studies-Study Design, Data Analysis and Implications for Dosing and Labeling, 2004. Available from: .
12. Fischer G. Treatment of opioid dependence in pregnant women. Addiction 95 (2000) 1141-1144
13. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 (2004) 1802-1811
14. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., and Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268 (1993) 21493-21496
15. Kandall S.R., Doberczak T.M., Jantunen M., and Stein J. The methadone-maintained pregnancy. Clin. Perinatol. 26 (1999) 173-183
16. Karabulut A.K., Ulger H., and Pratten M.K. Protection by free oxygen radical scavenging enzymes against salicylate-induced embryonic malformations in vitro. Toxicol. In Vitro 14 (2000) 297-307
17. Kitano T., Iizasa H., Terasaki T., Asashima T., Matsunaga N., Utoguchi N., Watanabe Y., Obinata M., Ueda M., and Nakashima E. Polarized glucose syncytiotrophoblast cell lines, TR-TBTs. J. Cell. Physiol. 193 (2002) 208-218
18. Kliman H.J., Nestler J.E., Sermasi E., Sanger J.M., and Strauss III J.F. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 118 (1986) 1567-1582
19. Komorowski J., Jerczynska H., Siejka A., Baranska P., Lawnicka H., Pawlowska Z., and Stepien H. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. 78 (2006) 2558-2563
20. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., and Umbenhauer D.R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12 (1998) 457-463
21. Lin J.H., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42 (2003) 59-98
22. MacFarland A., Abramovich D.R., Ewen S.W., and Pearson C.K. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. 26 (1994) 417-423
23. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (2001) 3458-3464
24. Mao Q. BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm. Res. 25 (2008) 1244-1255
25. Marin J.J., Briz O., and Serrano M.A. A review on the molecular mechanisms involved in the placental barrier. Curr. Drug Deliv. 1 (2004) 275-289
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
27. Nanovskaya T., Nekhayeva I., Karunaratne N., Audus K., Hankins G.D., and Ahmed M.S. Role of P-glycoprotein in transplacental transfer of methadone. Biochem. Pharmacol. 69 (2005) 1869-1878
28. Nasca M.R., O'Toole E.A., Palicharla P., West D.P., and Woodley D.T. Thalidomide increases human keratinocyte migration and proliferation. J. Invest. Dermatol. 113 (1999) 720-724
29. Nelson D.M., and Walsh S.W. Aspirin differentially affects thromboxane and prostacyclin production by trophoblast and villous core compartments of human placental villi. Am. J. Obstet. Gynecol. 161 (1989) 1593-1598
30. Neubert D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratog. Carcinog. Mutagen 17 (1997) i-ii
31. Novotna M., Libra A., Kopecky M., Pavek P., Fendrich Z., Semecky V., and Staud F. P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod. Toxicol. 18 (2004) 785-792
32. Pascolo L., Fernetti C., Pirulli D., Crovella S., Amoroso A., and Tiribelli C. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem. Biophys. Res. Commun. 303 (2003) 259-265
33. Pavek P., Fendrich Z., Staud F., Malakova J., Brozmanova H., Laznicek M., Semecky V., Grundmann M., and Palicka V. Influence of P-glycoprotein on the transplacental passage of cyclosporine. J. Pharm. Sci. 90 (2001) 1583-1592
34. Pavek P., Staud F., Fendrich Z., Sklenarova H., Libra A., Novotna M., Kopecky M., Nobilis M., and Semecky V. Examination of the functional activity of P-glycoprotein in the transplacental barrier using rhodamine 123. J. Pharmacol. Exp. Ther. 305 (2003) 1239-1250
35. Rotem R., Tzivony Y., and Flescher E. Contrasting effects of aspirin on prostate cancer cells: suppression of proliferation and induction of drug resistance. Prostate 42 (2000) 172-180
36. Sibley C.P., Turner M.A., Cetin I., Ayuk P., Boyd C.A., D'Souza S.W., Glazier J.D., Greenwood S.L., Jansson T., and Powell T. Placental phenotypes of intrauterine growth. Pediatr. Res. 58 (2005) 827-832
37. Smit J.W., Huisman M.T., van Tellingen O., Wiltshire H.R., and Schinkel A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104 (1999) 1441-1447
38. Somers G.F. Thalidomide and congenital abnormalities. Lancet 1 (1962) 912-913
39. Staub F., Vackova Z., Pospechova K., Pavek P., Ceckova M., Libra A., Cygalova L., Nachtigal P., and Fendrich Z. Expression and transport activity of breast cancer resistance protein (Bcrp/ABCG2) in dually perfused rat placenta and HRP-1 cell line. J. Pharmacol. Exp. Ther. 319 (2006) 53-62
40. St-Pierre M.V., Serrano M.A., Macias R.I., Dubs U., Hoechli M., Lauper U., Meier P.J., and Marin J.J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279 (2000) R1495-R1503
41. TERIS http://www.thomsonhc.com/ last reviewed May 2006.
42. Utoguchi N., Chandorkar G.A., Avery M., and Audus K.L. Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells. Reprod. Toxicol. 14 (2000) 217-224
43. Wang Y., and Walsh S.W. Aspirin inhibits both lipid peroxides and thromboxane in preeclamptic placentas. Free Radic. Biol. Med. 18 (1995) 585-591
44. Wolff K., Boys A., Rostami-Hodjegan A., Hay A., and Raistrick D. Changes to methadone clearance during pregnancy. Eur. J. Clin. Pharmacol. 61 (2005) 763-768
45. Yang X., Hu Z., Chan S.Y., Ho P.C., Chan E., Duan W., Goh B.C., and Zhou S. Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J. Pharm. Biomed. Anal. 39 (2005) 299-304
46. Yang X.X., Hu Z.P., Xu A.L., Duan W., Zhu Y.Z., Huang M., Sheu F.S., Zhang Q., Bian J.S., Chan E., Li X., Wang J.C., and Zhou S.F. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J. Pharmacol. Exp. Ther. 319 (2006) 82-104
47. Ylikorkala O., Makila U.M., Kaapa P., and Viinikka L. Maternal ingestion of acetylsalicylic acid inhibits fetal and neonatal prostacyclin and thromboxane in humans. Am. J. Obstet. Gynecol. 155 (1986) 345-349
48. Young A.M., Allen C.E., and Audus K.L. Efflux transporters of the human placenta. Adv. Drug Deliv. Rev. 55 (2003) 125-132
49. Zimmermann C., Gutmann H., and Drewe J. Thalidomide does not interact with P-glycoprotein. Cancer Chemother. Pharmacol. 57 (2006) 599-606